Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest abdominal pain Stories

2012-10-22 07:30:36

SAN DIEGO, Oct. 22, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, will present five abstracts at the American College of Gastroenterology 2012 Scientific Meeting taking place this week in Las Vegas, NV. These data add to the compelling body of evidence that supports standardized use of liquid phase assays in helping to identify potential causes for loss of treatment response among inflammatory bowel disease (IBD) patients using...

2012-10-22 07:29:39

LAS VEGAS, Oct. 22, 2012 /PRNewswire/ -- New Phase 3 study findings showed significantly more patients with moderately to severely active ulcerative colitis (UC) who responded to induction therapy with subcutaneously administered SIMPONI(®) (golimumab) maintained clinical response through week 54, the primary endpoint of the study, compared with patients receiving placebo. Investigators will report clinical response, clinical remission and mucosal healing results through one year from...

2012-10-18 11:25:43

ATLANTA, Oct. 18, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology and neuroscience treatment and research, is marking the 2012 American College of Gastroenterology (ACG) Annual Scientific meeting in Las Vegas, Nevada by reinforcing its commitment to improving the lives of patients with Crohn's disease. UCB will present scientific data at this year's ACG meeting, October 19-24. "The annual ACG meeting gives UCB the opportunity to demonstrate our ongoing...

2012-10-11 04:00:54

Synechion, Inc., a research and consulting company specializing in the prevention of adhesions - internal scars causing pain and other complications - has announced the formation of a new company, KevMed, LLC to commercialize break-through innovations for the treatment of chronic pelvic pain and related disorders. Over 15 million patients in the U.S. suffer from chronic pelvic pain with very few effective treatment options currently available. Dallas, TX, (PRWEB) October 10, 2012 Synechion...

2012-10-08 15:22:25

SAN DIEGO, Oct. 8, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing rescue therapies for patients in ischemic crisis, today announced the completion of patient enrollment in its Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment in severely injured trauma patients experiencing hemorrhagic shock. MP4OX is a novel ischemic rescue therapy designed to improve perfusion and oxygen delivery to tissues. (Logo:...

2012-09-29 23:02:16

G-Tech has obtained IRB approval to launch a clinical research study designed to record abnormal myoelectrical activity in subjects with irritable bowel syndrome (IBS). Palo Alto, Calif. (PRWEB) September 28, 2012 G-Tech, an early stage medical device company, announced today that it has received IRB approval to launch a six-month, 60-subject clinical research study designed to record abnormal myoelectrical activity in subjects with abdominal pain associated with irritable bowel syndrome...

2012-09-13 02:27:20

PRINCETON, N.J., Sept. 13, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the company), a development stage biopharmaceutical company announced today that the US Patent Office granted patent 8,263,582 entitled "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of beclomethasone dipropionate (BDP) in orally administered dosage forms that act...

shutterstock_3366007
2012-09-09 09:07:25

redOrbit Staff & Wire Reports — Your Universe Online An estimated 25% of all professional volleyball players surveyed as part of a recent study demonstrated symptoms associated with a shoulder artery injury that could cause irreversible damage to a person's fingers, the Dutch authors of the study have reported. Dr. Mario Maas, senior author of the study and a radiologist at the University of Amsterdam Academic Medical Center, and colleagues began their research after having...

2012-09-06 02:31:26

PRINCETON, N.J., Sept. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of pediatric Crohn's disease. Soligenix has previously received Orphan Drug Designation for oral BDP...

2012-09-04 06:27:27

PHILADELPHIA, Sept. 4, 2012 /PRNewswire/ -- AFCell Medical announced today the results of a retrospective study of the use of an amnion based allograft membrane to prevent post-operative adhesions between the tendon, peritendonous structures and overlying skin. Of the fourteen study patients, 86% were clear of adhesions anywhere around the surgery site and 93% were adhesion free at the tendon repair site 1.7 years post-surgery, on average, and of those patients with signs of adhesions the...